

Cover Story
Free
Congressional Panel Chair Questions Whether J&J, Brigham Reported Morcellation Adverse Events to FDA
By Matthew Bin Han Ong
The House Committee on Energy & Commerce has stepped into a key role in the controversy over power morcellation.
In Brief


Drugs & Targets
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years











